drugset / Trial / NCT02572752
Relative Bioavailability of 2 Oral Formulations of Nintedanib
RandomizedCrossoverOpen-labelTreatment
Summary
To establish the bioequivalence of 1 soft gelatine capsule containing 200 mg nintedanib compared to 2 soft gelatine capsules containing 100 mg nintedanib
Timeline
- Start
- 2015-08
- Primary completion
- 2015-11
- Completion
- 2015-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Nintedanib | Small molecule | 100 mg | Oral |
| Subject | Nintedanib | Small molecule | 200 mg | Oral |
Indications
No indication recorded.